superior at month 24 to other dosages tested and statistically superior to placebo in preserving visual acuity (p≤0.05). In the anecortave acetate group, 73% of patients maintained vision compared with 47% in the sham group. In the sham-treated group 23% of patients went on to severe vision loss compared with 6% in the anecortave acetate treated group (p≤0.05). Anecortave acetate also demonstrated the ability to inhibit the growth of classic CNV (p≤0.05) in eyes with all lesion types. Beginning at six months and continuing throughout the entire 24- month study, anecortave acetate 15mg was consistently more effective in stabilizing vision compared with placebo. The following mild and transient conditions were noted post administration: ptosis, subconjunctival hemorrhage, ocular discomfort, ocular pruritus, hyperemia, and foreign body sensation (see also Table 4). The clinical efficacy observed in this study of a mixed population of AMD lesion types and sizes supports earlier observations that anecortave acetate is likely to inhibit CNV lesion growth regardless of lesion subtype. C-00-07: anecortave acetate suspension and PDT combination trial C-00-07 was a 6-month phase II study that evaluated the effect of anecortave acetate (15 mg or 30 mg) versus placebo Aneaccoerttaavtee Inhibition Nucleus uXPA (Urokinase Plasminogen Activator) PAI-1 (Plasminogen Activator Inhibitor-1) Anecortave acetate in age-related macular degeneration following initial Visudyne PDT, for the treatment of patients with exudative AMD. This study enrolled 136 patients and was completed in 2002. Patients who received a single administration of anecortave acetate following initial treatment with PDT maintained better vision than patients who received PDT alone. Data from this study illustrated that anecortave acetate can be safely administered with PDT. C-01-99: pivotal study versus Visudyne PDT: RETAANE suspension plus sham PDT versus Visudyne PDT plus sham PJD This pivotal, non-inferiority study was designed to compare anecortave acetate 15 mg suspension to PDT with verteporfin. The 530 exudative AMD patients enrolled in this study were randomized 1:1 to either a PJD administration of anecortave acetate 15 mg every six months combined with a sham PDT treatment every three months per labeling guidelines, or to PDT every three months combined with a sham PJD administration every six months. This trial confirmed the excellent safety results reported in C-98-03 study. At 12 months 45% of anecortave acetate 15 mg-treated patients had preserved vision compared with 49% in the PDT group (p>0.05) which was not significantly different (Slakter et al 2006). The study demonstrated that anecortave acetate and verteporfin PDT treatments are clinically equivalent throughout 24 months following VEC proliferation and migration Dissolution of basement membrane Extracellular Matrix breakdown Matrix- Metalloproteinases (MMP) Pro-MMP- Activation Plasminogen X Plasmin Figure 5 Anecortave acetate blocks proteolytic cascade in the vascular endothelial cells (VEC). Clinical Interventions in Aging 2006:1(3) 243